Normal cognitive behavior in two distinct congenic lines of transgenic mice hyperexpressing mutant APPSWE
Amyloid deposition appears to be an early and crucial event in Alzheimer’s disease (AD). To generate animal models of AD, mice expressing full-length amyloid precursor protein (APP), with mutations linked to FAD, have been created. These animals exhibit abnormalities characteristic of AD, including...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2003-04-01
|
Series: | Neurobiology of Disease |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0969996102000128 |
id |
doaj-fd5a976eeb6d4d888e2ac2829326c61a |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Alena V Savonenko Guilian M Xu Donald L Price David R Borchelt Alicja L Markowska |
spellingShingle |
Alena V Savonenko Guilian M Xu Donald L Price David R Borchelt Alicja L Markowska Normal cognitive behavior in two distinct congenic lines of transgenic mice hyperexpressing mutant APPSWE Neurobiology of Disease Place discrimination Water maze Longitudinal Cross-sectional Memory β-Amyloid |
author_facet |
Alena V Savonenko Guilian M Xu Donald L Price David R Borchelt Alicja L Markowska |
author_sort |
Alena V Savonenko |
title |
Normal cognitive behavior in two distinct congenic lines of transgenic mice hyperexpressing mutant APPSWE |
title_short |
Normal cognitive behavior in two distinct congenic lines of transgenic mice hyperexpressing mutant APPSWE |
title_full |
Normal cognitive behavior in two distinct congenic lines of transgenic mice hyperexpressing mutant APPSWE |
title_fullStr |
Normal cognitive behavior in two distinct congenic lines of transgenic mice hyperexpressing mutant APPSWE |
title_full_unstemmed |
Normal cognitive behavior in two distinct congenic lines of transgenic mice hyperexpressing mutant APPSWE |
title_sort |
normal cognitive behavior in two distinct congenic lines of transgenic mice hyperexpressing mutant appswe |
publisher |
Elsevier |
series |
Neurobiology of Disease |
issn |
1095-953X |
publishDate |
2003-04-01 |
description |
Amyloid deposition appears to be an early and crucial event in Alzheimer’s disease (AD). To generate animal models of AD, mice expressing full-length amyloid precursor protein (APP), with mutations linked to FAD, have been created. These animals exhibit abnormalities characteristic of AD, including deposits of β-amyloid (Aβ), neuritic plaques, and glial responses. In studies of cognition in these animals, there have been several reports of memory disturbances well before the appearance of amyloid deposits. We have developed two distinct lines of transgenic mice (C3-3 and E1-2) that express the “Swedish” variant of APP (APPSWE) at levels that are approximately three-fold higher than endogenous mouse APP. Both lines have been backcrossed to C57BL/6J mice for 10 generations. Here, we use longitudinal and cross-sectional studies to evaluate the cognitive performance of our animals, where the concentration of Aβ1-42 in brain increases with aging from low levels (2–10 pmol/g) at 6–14 months of age to relatively high levels (60–100 pmol/g) at 24–26 months, when deposits of Aβ were beginning to form. When 12-month-old mice were tested in tasks that assess reference and working memory, transgenic mice from both lines could not be distinguished from nontransgenic littermates. Further study of 24- to 26-month-old transgenic mice (C3-3 line) found no evidence of memory impairment despite the presence of high levels of human Aβ (60–100 pmol/g). Thus, the expression of APPSWE at approximately three-fold over endogenous levels, which is sufficient to induce amyloid deposition at advanced ages, does not significantly erode cognitive performance in aged mice. |
topic |
Place discrimination Water maze Longitudinal Cross-sectional Memory β-Amyloid |
url |
http://www.sciencedirect.com/science/article/pii/S0969996102000128 |
work_keys_str_mv |
AT alenavsavonenko normalcognitivebehaviorintwodistinctcongeniclinesoftransgenicmicehyperexpressingmutantappswe AT guilianmxu normalcognitivebehaviorintwodistinctcongeniclinesoftransgenicmicehyperexpressingmutantappswe AT donaldlprice normalcognitivebehaviorintwodistinctcongeniclinesoftransgenicmicehyperexpressingmutantappswe AT davidrborchelt normalcognitivebehaviorintwodistinctcongeniclinesoftransgenicmicehyperexpressingmutantappswe AT alicjalmarkowska normalcognitivebehaviorintwodistinctcongeniclinesoftransgenicmicehyperexpressingmutantappswe |
_version_ |
1724212194122399744 |
spelling |
doaj-fd5a976eeb6d4d888e2ac2829326c61a2021-03-20T04:47:36ZengElsevierNeurobiology of Disease1095-953X2003-04-01123194211Normal cognitive behavior in two distinct congenic lines of transgenic mice hyperexpressing mutant APPSWEAlena V Savonenko0Guilian M Xu1Donald L Price2David R Borchelt3Alicja L Markowska4Department of Psychology, Johns Hopkins University, 3400 N. Charles Street, Baltimore, MD 21218, USA; Department of Pathology, Johns Hopkins School of Medicine, 720 Rutland Avenue, 558 Ross Building, Baltimore, MD 21205, USA; Department of Neuroscience, Johns Hopkins School of Medicine, 720 Rutland Avenue, 558 Ross Building, Baltimore, MD 21205, USA; Department of Neurology, Johns Hopkins School of Medicine, 720 Rutland Avenue, 558 Ross Building, Baltimore, MD 21205, USADepartment of Psychology, Johns Hopkins University, 3400 N. Charles Street, Baltimore, MD 21218, USA; Department of Pathology, Johns Hopkins School of Medicine, 720 Rutland Avenue, 558 Ross Building, Baltimore, MD 21205, USA; Department of Neuroscience, Johns Hopkins School of Medicine, 720 Rutland Avenue, 558 Ross Building, Baltimore, MD 21205, USA; Department of Neurology, Johns Hopkins School of Medicine, 720 Rutland Avenue, 558 Ross Building, Baltimore, MD 21205, USADepartment of Psychology, Johns Hopkins University, 3400 N. Charles Street, Baltimore, MD 21218, USA; Department of Pathology, Johns Hopkins School of Medicine, 720 Rutland Avenue, 558 Ross Building, Baltimore, MD 21205, USA; Department of Neuroscience, Johns Hopkins School of Medicine, 720 Rutland Avenue, 558 Ross Building, Baltimore, MD 21205, USA; Department of Neurology, Johns Hopkins School of Medicine, 720 Rutland Avenue, 558 Ross Building, Baltimore, MD 21205, USADepartment of Psychology, Johns Hopkins University, 3400 N. Charles Street, Baltimore, MD 21218, USA; Department of Pathology, Johns Hopkins School of Medicine, 720 Rutland Avenue, 558 Ross Building, Baltimore, MD 21205, USA; Department of Neuroscience, Johns Hopkins School of Medicine, 720 Rutland Avenue, 558 Ross Building, Baltimore, MD 21205, USA; Department of Neurology, Johns Hopkins School of Medicine, 720 Rutland Avenue, 558 Ross Building, Baltimore, MD 21205, USADepartment of Psychology, Johns Hopkins University, 3400 N. Charles Street, Baltimore, MD 21218, USA; Department of Pathology, Johns Hopkins School of Medicine, 720 Rutland Avenue, 558 Ross Building, Baltimore, MD 21205, USA; Department of Neuroscience, Johns Hopkins School of Medicine, 720 Rutland Avenue, 558 Ross Building, Baltimore, MD 21205, USA; Department of Neurology, Johns Hopkins School of Medicine, 720 Rutland Avenue, 558 Ross Building, Baltimore, MD 21205, USAAmyloid deposition appears to be an early and crucial event in Alzheimer’s disease (AD). To generate animal models of AD, mice expressing full-length amyloid precursor protein (APP), with mutations linked to FAD, have been created. These animals exhibit abnormalities characteristic of AD, including deposits of β-amyloid (Aβ), neuritic plaques, and glial responses. In studies of cognition in these animals, there have been several reports of memory disturbances well before the appearance of amyloid deposits. We have developed two distinct lines of transgenic mice (C3-3 and E1-2) that express the “Swedish” variant of APP (APPSWE) at levels that are approximately three-fold higher than endogenous mouse APP. Both lines have been backcrossed to C57BL/6J mice for 10 generations. Here, we use longitudinal and cross-sectional studies to evaluate the cognitive performance of our animals, where the concentration of Aβ1-42 in brain increases with aging from low levels (2–10 pmol/g) at 6–14 months of age to relatively high levels (60–100 pmol/g) at 24–26 months, when deposits of Aβ were beginning to form. When 12-month-old mice were tested in tasks that assess reference and working memory, transgenic mice from both lines could not be distinguished from nontransgenic littermates. Further study of 24- to 26-month-old transgenic mice (C3-3 line) found no evidence of memory impairment despite the presence of high levels of human Aβ (60–100 pmol/g). Thus, the expression of APPSWE at approximately three-fold over endogenous levels, which is sufficient to induce amyloid deposition at advanced ages, does not significantly erode cognitive performance in aged mice.http://www.sciencedirect.com/science/article/pii/S0969996102000128Place discriminationWater mazeLongitudinalCross-sectionalMemoryβ-Amyloid |